Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development;Znaczenie zespołu antyfosfolipidowego i przeciwciał antyfosfolipidowych u chorych na toczeń rumieniowaty układowy w ocenie ryzyka rozwoju subklinicznej miażdżycy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue SUPPL., 2007, Pages 13-17

  Fischer, Katarzyna ^a   Brzosko, Marek ^a   Walecka, Anna ^a   Ostanek, Lidia ^a   Sawicki, Marcin ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Atherosclerosis; Intima media thickness; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CLINICAL EVALUATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 36549062936     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975; 58: 243-264.
2. Urowitz MB, Bookman AAM, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60: 221-225.
3. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004; 110: 399-404.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809.
5. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003; 62: 1071-1077.
6. O'Leary DH, Polak JF, Kronmai RA, et al. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340: 14-22.
7. Medina G, Casaos D, Jara LJ, et al. Iccreased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003; 62: 607-610.
8. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44: 2331-2337.
9. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277.
10. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999; 42: 1309-1311.
11. Fischer K, Brzosko M, Walecka A, et al. Przeciwciała przeciwko komórkom endotelialnym - czynnik ryzyka miażdżycy u chorych na toczeń rumieniowaty układowy. Ann Acad Med Stet. 2006; 52 (Suppl 2): 95-99.
12. Luft S. Metody diagnostyki serologicznej w reumatologii. Wykrywanie antykoagulantu tocznia. Warszawa, Wyd Nauk PWN, 1996: 136-155.
13. Stata Statistical Software: Release 5. College Stadion, TX: Stata Corporation, 1997.
14. Manzi S, Kuller LH, Edmundowicz D, Sutton-Tyrrell K. Vascular imaging: changing the face of cardiovascular research. Lupus. 2000; 9: 176-182.
15. Denarié N, Gariepy J, Chironi G, et al. Distribution of ultrasonographically - assessed dimensions of common carotid arteries in healthy adults of both sexes. Atherosclerosis. 2000; 148: 297-302.
16. Sun Y, Lin CH, Lu CJ, et al. Carotid atherosclerosis, intima-media thickness and risk factors - an analysis of 1781 asymptomatic subjects in Taiwan. Atherosclerosis. 2002; 164: 89-94.
17. Homma S, Hirose N, Ishida H, et al. Carotid plaque and intima-media thickness assessed by B-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke. 2001; 32: 830-835.
18. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima-media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women. Stroke. 1999; 30: 841-850.
19. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001; 104: 1887-1893.
20. Dropiński J, Szczeklik W, Wȩgrzyn W. Wzmożona grubość błony środkowej i wewnȩtrznej tȩtnic szyjnych w chorobach układowych tkanki ła̧ cznej jako zwiastun miażdżycy. Kardiol Pol. 2003; 59: 479-483.
21. Walecka A, Sawicki M, Brzosko M, et al. Value of high resistance index-HRI calculated from Doppler spectrum of popliteal arteries in patients with systemic lupus erythematosus (SLE). Med Sci Monit. 2004; 10 (Suppl 3): 58-62.
22. Ostanek L, Brzosko M, Fischer K, Płońska E. Zespół antyfosfolipidowy i przeciwciała antyfosfolipidowe jako czynniki ryzyka choroby wieńcowej i zawału serca u chorych na toczeń rumieniowaty układowy. Pol Arch Med Wewn. 2006; 115: 407-413.
23. Ostanek L, Płońska E, Peregud-Pogorzelska M, et al. Zmiany w układzie sercowonaczyniowym u chorych na toczeń rumieniowaty układowy w oparciu o badania echokardiograficzne. Pol Merk Lek. 2006; 117: 305-308.
24. De Souza AGS, Hatta FS, Miranda F, Sato EI. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J. 2005; 123: 137-142.
25. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004; 3: 423-453.
26. Jimenez S, Garcia-Criado MA, Tássies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology. 2005; 44: 756-761.
27. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JPA, et al. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology. 2003; 42: 645-651.
28. Meissner M, Chwalińska-Sadowska H, Butkiewicz L, et al. Zespół antyfosfolipidowy (APS) pierwotny (PAPS) i wtórny (SAPS) jako czynnik ryzyka miażdżycy. Twój Mag Med. 2005; 3: 49-53.
29. Glueck CJ, Lang JE, Tracy T, et al. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol. 1999; 83: 1490-1494.
30. Takashi W, Tsutomu F, Kentaro F. Ultrasonic correlates of common carotid atherosclerosis in patients with coronary artery disease. Angiology. 2002; 53: 177-183.
31. Falaschi F, Ravelli A, Martignoni A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2000; 43: 1405-1409.